Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference
Stock Information for Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Loading
Please wait while we load your information from QuoteMedia.